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Abstract
Background: In locally advanced rectal cancer, 5-Fluorouracil (5-FU)-based chemoradiation is the
standard treatment. The main acute toxicity of this treatment is enteritis. Due to its potential
radiosensitizing properties, oxaliplatin has recently been incorporated in many clinical
chemoradiation protocols. The aim of this study was to investigate to what extent 5-FU and
oxaliplatin influence the radiation (RT) induced small bowel mucosal damage when given in
conjunction with single or split dose RT.
Methods: Immune competent balb-c mice were treated with varying doses of 5-FU, oxaliplatin
(given intraperitoneally) and total body RT, alone or in different combinations in a series of
experiments. The small bowel damage was studied by a microcolony survival assay. The treatment
effect was evaluated using the inverse of the slope (D0) of the exponential part of the dose-
response curve.
Results: In two separate experiments the dose-response relations were determined for single
doses of RT alone, yielding D0 values of 2.79 Gy (95% CI: 2.65 - 2.95) and 2.98 Gy (2.66 - 3.39), for
doses in the intervals of 5-17 Gy and 5-10 Gy, respectively. Equitoxic low doses (IC5) of the two
drugs in combination with RT caused a decrease in jejunal crypt count with significantly lower D0:
2.30 Gy (2.10 - 2.56) for RT+5-FU and 2.27 Gy (2.08 - 2.49) for RT+oxaliplatin. Adding both drugs
to RT did not further decrease D0: 2.28 Gy (1.97 - 2.71) for RT+5-FU+oxaliplatin. A clearly higher
crypt survival was noted for split course radiation (3 × 2.5 Gy) compared to a single fraction of 7.5
Gy. The same difference was seen when 5-FU and/or oxaliplatin were added.
Conclusion: Combining 5-FU or oxaliplatin with RT lead to an increase in mucosal damage as
compared to RT alone in our experimental setting. No additional reduction of jejunal crypt counts
was noted when both drugs were combined with single dose RT. The higher crypt survival with
split dose radiation indicates a substantial recovery between radiation fractions. This mucosal-
sparing effect achieved by fractionation was maintained also when chemotherapy was added.
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Surgery is the cornerstone of curative therapy for colorec-
tal cancer. In locally advanced cases, radiotherapy is used
preoperatively to shrink the tumor in order to facilitate a
curative resection. An improved effect has been shown
when radiation is combined with the chemotherapeutic
agent, 5-fluorouracil (5-FU) [1-3]. This has made 5-FU-
based chemoradiation a standard treatment for locally
advanced rectal cancer. Another drug, oxaliplatin, has
become widely used in adjuvant [4], as well as palliative
[5,6] treatment of colorectal cancer. Several phase II stud-
ies indicate good efficacy when oxaliplatin was combined
with 5-FU or oral fluoropyrimidines such as capecitabine
and radiotherapy [7-11]. Preclinical studies have demon-
strated that both 5-FU and oxaliplatin have radiosensitiz-
ing properties on tumor cell lines in vitro [12,13], while
the additional effect of oxaliplatin in vivo is more uncer-
tain [13,14].
The main dose-limiting acute side effect during abdomi-
nal radiation is enteritis. Randomized studies have shown
that combined treatment with radiation and 5-FU
increases the risk of diarrhea as compared to radiotherapy
alone [2]. There are no published results from rand-
omized trials on whether the addition of oxaliplatin fur-
ther increases gastrointestinal toxicity, but the
combination of 5-FU (or capecitabine), oxaliplatin and
radiotherapy has lead to 12-37% grade 3+ enteritis in
phase II trials [7-11].
The regeneration of the bowel mucosa is dependent on its
clonogenic stem cells which are located in the small bowel
crypts. Therefore, the survival of these clonogens is likely
to be a decisive factor in the repair of the bowel after cyto-
toxic therapy. The pioneering work of Withers and Elkind
presented in 1970 has given us the opportunity to study
this in the mouse intestinal mucosa [15]. Development of
radiation enteritis is thought to be mediated through a
toxic effect on these mucosal stem cells. The aim of this
study was to study the bowel damage caused by radiation,
5-FU or oxaliplatin as well as combinations thereof by
using a microcolony survival assay and comparing the dif-
ference between single and split dose radiotherapy.
Methods
Mice
Immune competent balb-c mice were used. The mice were
treated at the age of six to seven weeks and were housed in
well-ventilated lucite boxes with food and water ad libi-
tum. The study was approved by the Malmö-Lund animal
ethics committee.
Irradiation
Total body irradiation was administered with a 6 MV pho-
ton beam from a medical linear accelerator at a dose rate
of 3 Gy/min. The animals were treated five at a time in a
lucite box, specially designed for obtaining a homoge-
nous total body dose (within ± 5%) and for gentle fixation
of the animals. Control animals were sham irradiated. The
time of radiation was defined as time point 0. The radio-
therapy was given as a single fraction (0, 2.5, 5, 7.5, 10,
14, or 17 Gy) or as a split dose treatment with 2.5 Gy frac-
tions delivered two or three times with six-hour intervals.
Five mice were treated at each radiation dose level.
5-FU and oxaliplatin
Both drugs were administered intraperitoneally. Single
doses of 5-FU (Mayne Pharma) 0-200 mg/kg and of oxali-
platin (Mayne Pharma) 0-10 mg/kg were administered
alone or in combination with radiotherapy. When com-
bined, 5-FU was injected immediately followed by the
administration of oxaliplatin one hour prior to radiother-
apy. Control animals were given saline injection instead
of chemotherapy. For each different dose level, five mice
were treated.
Microcolony assay
A microcolony survival assay [15] was used to analyze
crypt survival after treatment. Three days after radiother-
apy or chemotherapy, the mice were killed by cervical dis-
location and a 10 cm section of the jejunum was collected,
stretched and pinned to a cork plate to ease histological
preparation. Tissues were fixed immediately in 4% forma-
lin with phosphate buffer and 10 transverse sections of
jejunum from each mouse were prepared and stained with
hematoxylin and eosin (H&E). These transverse sections
were analyzed microscopically, and a surviving colony
was defined as one demonstrating the presence of ten or
more well-stained cells in the section. The slides were ana-
lyzed by one observer (A.G.) in a blinded fashion.
Data analysis
The number of regenerating crypts/circumference was
counted for each section from each treated (t) or
untreated (control, c) animal. The surviving crypt fraction
was thus t/c and the proportion of crypts destroyed/trans-
verse section was 1-t/c. Since ten transverse sections were
obtained from each mouse and five mice were used for
each treatment dose, each data point was composed of a
maximum of 50 observations. A linear regression was
done to estimate D0, i.e., the inverse of the slope of the
exponential part of the survival curve, for radiotherapy
alone and for the combinations of 5-FU and/or oxalipla-
tin with radiotherapy. The Mann-Whitney test was used to
compare crypt survival after single versus split-dose radio-
therapy. All tests were two-sided and p-values < 0.05 were
considered statistically significant.
Experimental design
Four sets of experiments were performed as follows:Page 2 of 7
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ranging from 0 - 17 Gy, with the purpose of describing the
dose-response relations in our experimental setting and
finding appropriate doses for the combined treatment
(step 3).
2. The effect of each drug alone, at different doses, was
studied to find suitable doses which produced moderate
and equal intestinal damage. These doses were then com-
bined with radiation in the next step.
3. Single radiation fractions, ranging from 0 - 10 Gy, were
given alone, or in combination with equitoxic single
doses of 5-FU, oxaliplatin, or both drugs.
4. The same single doses of 5-FU and oxaliplatin were
combined with split dose radiation.
Results
A total of 265 mice were used in the study. Nineteen died
before histological analysis: radiation alone (n = 4), 5-FU
alone (n = 1), oxaliplatin alone (n = 6), radiation + 5-FU
(n = 2), radiation + oxaliplatin (n = 3), radiation + 5-FU +
oxaliplatin (n = 2) and 5-FU + oxaliplatin (n = 1) and thus
246 mice were available for crypt analysis. A total of 2206
transverse sections (mean 45 sections per data point) were
available for analysis.
Radiotherapy
The first radiation series with doses of 0, 5, 7.5, 10, 14 and
17 Gy is visualized in Fig. 1A. The surviving crypts per cir-
cumference decreased with increasing radiation doses
showing a dose-response relationship. D0 was calculated
using data points for doses from 5 - 17 Gy where the dose-
effect curve was considered exponential. In this first exper-
iment we found a D0 of 2.79 Gy (95% CI: 2.65 - 2.95). The
highest radiation doses of 14 - 17 Gy caused a near com-
plete eradication of jejunal crypts (Fig. 1A). When plan-
ning the chemoradiation experiment, we assumed that
radiation doses of 14-17 Gy plus chemotherapy also
would lead to zero crypt count, and the highest radiation
doses were therefore omitted in the studies of combined
treatment. The result from the radiation alone experiment
with doses in the 0-10 Gy range is depicted in Fig. 1B,
demonstrating a D0 of 2.98 Gy (95% CI: 2.66 - 3.39).
Chemotherapy
5-FU administration decreased the surviving fraction of
crypts per circumference up to a dose of 150 mg/kg (Fig.
2A), followed by a further, slight increase in the mean
crypt level at the highest 5-FU dose (200 mg/kg). In order
to rule out a methodological error as an explanation for
this finding, these two 5-FU doses were reevaluated in a
separate experiment, which confirmed our original result,
although again with large error bars at this dose level.
Increasing doses of oxaliplatin resulted in an essentially
linear decrease in the number of surviving crypts in the
dose range from 6 to 10 mg/kg (Fig. 2B).
Chemoradiation - single fraction radiation
The experiment described above (Fig. 2A-B) showed that
a 5-FU dose of 50 mg/kg and an oxaliplatin dose of 6 mg/
kg each had a modest and equal effect on the intestinal
crypts, and these doses were chosen for combination with
radiation.
The addition of 5-FU (Fig. 1C) or oxaliplatin (Fig. 1D) to
radiotherapy significantly decreased the number of surviv-
ing crypts per circumference as compared to radiation
alone. The D0 for radiation decreased from 2.98 Gy to
2.30 Gy (p = 0.001) and 2.27 Gy (p = 0.0003) when 5-FU
and oxaliplatin were added respectively.
The combination of both oxaliplatin and 5-FU with radi-
otherapy did not lead to any further decrease in D0 as
compared to the addition of each drug alone (Fig. 1E-F).
Split-dose radiotherapy
Splitting the radiation dose into two or three fractions
lead to significantly more surviving crypts per circumfer-
ence as compared to the same total dose given in one frac-
tion (Table 1), with the largest difference noted for 3 × 2.5
Gy compared to 7.5 Gy as a single treatment. Also when
adding chemotherapy, there were clearly more surviving
crypts with fractionated radiation compared to chemo-
therapy plus the same radiation dose given as a single
dose.
Discussion
This is to our knowledge the first study on chemoradia-
tion-induced bowel mucosal damage in mice including
oxaliplatin. A dose relationship was confirmed between
radiation dose and crypt survival (Fig. 1A-B). Adding 5-FU
or oxaliplatin lead to a significant increase in jejunal crypt
damage, in terms of decreased D0, compared to radiation
alone (Fig. 1C-D). The co-administration of both drugs
did not further increase radiation induced mucosal dam-
age (Fig. 1E). Fractionated radiation caused less mucosal
damage than the same total dose given as a single fraction.
This damage-sparing effect by fractionating the radiation
was retained also when chemotherapy was added (Table
1).
The initial part of our study aimed at determining the
mucosal injury caused by radiation alone. In the two
series using radiation doses up to 17 Gy and 10 Gy, we
found D0 values of 2.79 and 2.98, respectively, which is
higher than usually reported in the literature (typically in
the range 1-1.5 [16,17]). In those studies D0 was calcu-
lated at radiation doses ranging from around 9 - 14 GyPage 3 of 7
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The number of surviving crypts per circumference and D0with 95% confidence interval after AFigure 1
The number of surviving crypts per circumference and D0with 95% confidence interval after A. Radiotherapy (1st 
experiment, 0-17 Gy), B. Radiotherapy (2nd experiment, 0-10 Gy), C. 5-FU + radiotherapy (0-10 Gy), D. Oxaliplatin + radio-
therapy (0-10 Gy) and E. 5-FU + oxaliplatin + radiotherapy (0-10 Gy). F. Survival curves for all treatment combinations above 
with separate data points removed for clarity. Each data point represents the mean in each group and the error bars 1 SD. 
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Radiation Oncology 2009, 4:61 http://www.ro-journal.com/content/4/1/61[17], compared to 5 Gy and higher in the present study.
Using only data points from 7.5 or 10 Gy and higher did
not significantly decrease the D0 in our study (data not
shown). One possible explanation for the inter-study dis-
crepancies could be variations in inherent radiosensitivity
between different mouse strains [18]. Since radiation
doses of 14 to 17 Gy lead to a near complete eradication
of jejunal crypts, we chose to use only doses up to 10 Gy
in the combined chemoradiation experiments. Besides,
the aim of our study was not to determine the absolute D0
values but rather to investigate the relative impact on jeju-
nal damage by adding 5-FU and oxaliplatin to radiation.
5-FU has been subjected to several previous studies using
murine models. The doses chosen for our experiments
have shown antitumoral efficacy with reasonable toxicity
in these studies [19]. We found that doses above 100 mg/
kg resulted in surviving fractions between 20 and 40%
(Fig. 2A), which indicates a stronger cytotoxic effect than
previous studies using the microcolony assay for 5-FU
[20]. One explanation for this lower clonogenic cell recov-
ery may be the slightly shorter time span from treatment
to analysis compared to other similar studies [20].
Regarding oxaliplatin, no previous studies have been pub-
lished on its effect on jejunal clonogenic crypt survival,
neither alone nor in combination with radiotherapy. The
oxaliplatin doses tested, from 4 to 10 mg/kg, have previ-
ously been used in combination with radiotherapy in
xenografted mice and have shown antitumoral effect and
limited general toxicity [14]. Our study showed a slight to
moderate drop in jejunal crypt surviving fraction within
that dose range (Fig. 2B), when administering oxaliplatin
alone.
In the chemoradiation experiments we used chemother-
apy doses that caused a low degree of mucosal damage on
their own. This principle is often applied also in the clini-
cal setting. Despite these low doses we saw a significant
reduction of the D0 values by adding either of the two
drugs to radiation compared to radiation alone, which
indicates that both 5-FU and oxaliplatin may potentiate
radiation-induced mucosal damage. However, there was
no additional jejunal injury when both drugs were added
to radiation.
When treating patients with colorectal cancer, radiation
doses higher than 5 Gy per fraction are usually not used,
especially not in combination with chemotherapy. To bet-
ter mimic the clinical situation, we investigated the effect
of fractionated radiation. Compared with 5 and 7.5 Gy as
a single dose, 2 and 3 × 2.5 Gy resulted in considerably
less jejunal damage (Table 1), indicating a substantial cel-
lular recovery during the 6 h time span between radiation
fractions. The fact that there was no significant reduction
of crypt survival when chemotherapy was added to split
dose radiation, indicates that neither 5-FU nor oxaliplatin
seem to abolish the mucosal-sparing effect achieved by
fractionating the radiation. To elucidate this further a
larger study with graded fraction doses is needed where
alpha/beta values for these treatments can be calculated.
How do these results correlate to the clinical experience?
5-FU is known to cause mucositis, which can involve the
intestines and cause enteritis. Depending on the schedule
of administration, the frequencies of grade 3-4 diarrhea
were 3% and 7% for infusional and bolus regimens,
respectively, in a randomized trial [21].
For oxaliplatin as single treatment, a grade 3-4 diarrhea
frequency of 6% has been reported [22]. For radiotherapy,
the relationship between toxicity and radiation dose is
well known with the grade of diarrhea also correlated with
the irradiated volume of the small bowel [23,24]. Addi-
tion of 5-FU to radiotherapy has been shown in two ran-
domized trials to increase the risk of enteritis [2,3]. Thus
The surviving fraction of crypts per circumference as a func-tion of chemotherapy doseFigure 2
The surviving fraction of crypts per circumference as 
a function of chemotherapy dose. A. 5-Fluorouracil (5-
FU), B. Oxaliplatin. Each data point stands for the mean of 
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Radiation Oncology 2009, 4:61 http://www.ro-journal.com/content/4/1/61the radiosensitization observed for 5-FU and oxaliplatin
alone in the present study is in concordance with clinical
experience.
Whether the combination of both drugs synergistically
leads to considerable increase in bowel toxicity is not well
known, since no randomized trials on this issue have been
published yet. Several phase I and II studies on oxalipla-
tin-based chemoradiation have been performed [7-11],
yielding grade 3-4 diarrhea that seems slightly higher (12-
37%) than in protocols using only 5-FU or capecitabine
together with radiotherapy [2,3,25,26]. In our experimen-
tal setting there were no signs of additional radiosensitiza-
tion when oxaliplatin was added to radiation and 5-FU
with identical D0 values (Fig. 1E-F) and no detrimental
effect on recovery (Table 1). Results from ongoing rand-
omized trials will show whether this is true also in the
clinical setting. One cannot exclude that using higher or
multiple chemotherapy doses, more radiation fractions or
different mouse strains would have led to a further
decrease in D0 when combining both drugs with radio-
therapy. The basis for this clonogenic assay is that the
regeneration of the bowel mucosa is dependent on its clo-
nogenic stem cells. Therefore, the survival of these clono-
gens is likely to be a decisive factor in the repair of the
bowel after cytotoxic therapy. However, it is possible that
other factors, such as inflammation and bacterial distur-
bances, also may add to chemoradiation-induced enteritis
in the clinical situation.
Conclusion
In conclusion, the addition of 5-FU or oxaliplatin to radi-
otherapy lead to a similar decrease in jejunal crypt survival
for both drugs. Adding the drugs together with radiation
did not further increase the mucosal damage in this exper-
imental setting.
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